Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 12/20 | 0.53 |
| ▸ | DRD2 | P14416 | 9/20 | 0.53 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | DRD5 | P21918 | 3/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16627001 | 0.92 | DRD1 (0.54) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL16625816 | 0.88 | DRD1 (0.45) | DRD1DRD2DRD3DRD5ADRA1D | |
| SCHEMBL16627052 | 0.85 | KCNH2 (0.57) | DRD1DRD2 | |
| SCHEMBL16627000 | 0.84 | DRD1 (0.57) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL13430577 | 0.82 | DRD1 (0.57) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL16625796 | 0.80 | DRD1 (0.47) | DRD1DRD2DRD3DRD5ADRA1D | |
| SCHEMBL16627024 | 0.80 | DRD1 (0.53) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL16627026 | 0.80 | DRD1 (0.53) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL13430580 | 0.80 | DRD1 (0.55) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL16627010 | 0.80 | DRD1 (0.55) | DRD1DRD2DRD3DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
| WO-2015051106-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | MALLINCKRODT LLC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | DRD1 2936/4885DRD2 2522/4885DRD3 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.